Luveris

Phase 3Small molecule

Merck & Co.

Luveris is one of 6 small molecule programs targeting Ovarian Stimulation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian StimulationCompleted

Ovarian StimulationPhase 3

Completed

Competition

Competitive Landscape

10 competitors in Ovarian Stimulation

#DrugCompanyPhaseTrials

Progestin

WWashington University School of Medicine

Phase 3

1 2

Luveris

Merck & Co.

Phase 3

3 3

Depo-Provera

Eli Lilly

Preclinical

1 4

Gynorest

SSolvay Pharmaceuticals

Preclinical

3 5

Trelstar

OOncoVerity, Inc.

Preclinical

1 6

Gonadotropin Releasing Hormone Antagonist

AAssiut University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Not yet recruiting

Ovarian Stimulation

NCT06227949

Clinical

Trials by Indication[1]

Ovarian Stimulation3 trials

FSH and LH Versus FSH Alone for Ovarian Stimulation in Non-hormone Sensitive Onco-fertility Patients

Not yet recruiting·EEllen Greenblatt·Phase 3·NCT06227949·140 enrolled

Synchronization of Follicle Wave Emergence and Ovarian Stimulation

Completed·UUniversity of Saskatchewan·Phase 4·NCT00439829·80 enrolled

A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT01497197·174 enrolled

Women1 trial

To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation

Unknown status·PPeking University Third Hospital·Phase 2·NCT01029470·150 enrolled

Hypogonadotropic Hypogonadism1 trial

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

Terminated· EMD Serono logo

EMD Serono·Phase 4·NCT00328926·11 enrolled

Unspecified1 trial

Pergoveris FD and Liquid China BE Study

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT04899193·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Luveris. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Luveris compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Luveris. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Luveris

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Ovarian Stimulation3 trials

Women1 trial

Hypogonadotropic Hypogonadism1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News